xten peptide XTEN peptide - XTENprotein is fused to a protein drug, using recombinant technology XTEN Peptide: Revolutionizing Drug Delivery for Extended Half-Life

XTENlinker sequence In the realm of pharmaceutical innovation, the ability to extend the therapeutic window of peptides and proteins has been a significant challenge.XtenCHO™ Race Transient Expression System Traditionally, polyethylene glycol (PEG) has been the go-to solution for half-life extension.2015年12月3日—Introduction of XTENs,unstructured hydrophilic polypeptides of defined amino acid compositionand low immunogenic potential, represents a ... However, emergent technologies offer compelling alternatives, with the XTEN peptide leading the charge. This advanced polypeptide platform is fundamentally changing how we approach drug delivery, offering a biological alternative that mimics PEG's functionality while introducing a host of unique advantages.

The core of XTEN technology lies in its design as an unstructured, hydrophilic and biodegradable protein polymer. Unlike rigid structures, XTEN forms a flexible, non-repetitive chain composed of specific hydrophilic amino acid building blocks, including alanine (A), glutamic acid (E), glycine (G), proline (P), serine (S), and threonine (T). This composition results in a large hydrodynamic volume and a negative charge, contributing to its enhanced pharmacokinetic properties作者：VN Podust·2013·被引用次数：56—Abstract.XTEN, unstructured biodegradable proteins, have been used to extend the in vivo half-life of genetically fused therapeutic proteins andpeptides.. These unstructured, nonrepetitive protein polymers are engineered with a defined amino acid composition and are designed to exhibit low immunogenic potential, a critical factor for therapeutic applications.

The Science Behind XTEN's Extended Half-Life

The primary function of XTEN is to significantly increase the half-lives of therapeutic peptides and proteins within the body, thereby reducing dosing frequency and improving patient compliance.XTEN-Annexin A5: XTEN Allows Complete Expression of ... This is achieved through a process often referred to as "XTENylation." When a polypeptide XTEN is genetically fused to a therapeutic peptide or protein, it creates a larger molecular entity.Peptide Therapy: Unlocking the Body's Potential for Healing and ... This increased size and hydrophilic nature reduce renal clearance, essentially "holding" the therapeutic molecule in circulation for longer periods.作者：A Haeckel·2014·被引用次数：36—So far,XTEN peptidehas been shown to be safe and nonimmunogenic in several animal species (7) and 2 XTEN-modified drugs have entered ... For instance, studies have shown that fusion with XTEN can lead to half-life extensions ranging from 60- to 130-fold over native molecules.

The XTEN polypeptide functions similarly to PEG by providing a bulky, hydrophilic shield around the active molecule. However, as a protein-based polymer, XTEN offers several key benefits.XTEN-Annexin A5: XTEN Allows Complete Expression of ... One of the most significant is its complete expression and production through recombinant technologyMultivalent Antiviral XTEN–Peptide Conjugates with Long in .... This means that XTEN-peptide conjugates can be manufactured as a single, homogeneous protein using well-established biopharmaceutical processes, such as the XtenCHO™ Race Transient Expression System, which delivers high yields and fast production without compromising quality. This stands in contrast to PEGylation, which is a chemical modification that can sometimes lead to heterogeneous products and potential immunogenicity concerns.

Applications and Verifiable Data

The versatility of the XTEN peptide is evident across a range of applications. It has been successfully employed to prolong the in vivo half-life of various biologically active molecules. For example, the development of Multivalent Antiviral XTEN–Peptide Conjugates with Long in vivo Half Life and Enhanced Solubility demonstrates its potential in creating long-acting antiviral therapies. Similarly, research into long circulating XTEN864-HGV-Apoptin fusion protein for therapeutic use underscores its ability to stabilize proteins and extend blood circulation time.Data suggest that chemical XTENylation could effectively extend the half-life of a wide spectrum of biologically active molecules, therefore broadening its ...

Furthermore, XTEN has been applied to imaging probes, such as XTEN-Annexin A5, to extend their blood half-life, improving diagnostic capabilities.XTENylation Service The XTEN sequence itself can be tailored to achieve specific pharmacokinetic profiles, allowing for tunable half-life extension. This tunability is crucial, as different therapeutic modalities require different circulating durations. For instance, Glucagon-like peptide 2 (GLP2) has been engineered with XTEN to create a pharmaceutical protein with improved properties for treating intestinal conditions.

Safety and immunogenicity are paramount in drug development. XTEN peptide has undergone rigorous testing and has demonstrated a favorable safety profile. Studies have indicated that XTEN peptide has been shown to be safe and non-immunogenic in several animal species, and some XTEN-modified drugs have already entered clinical development. The low immunogenic potential of XTEN compared to some other protein-based therapies is a significant advantageAmunix, Inc. And PolyPeptide Laboratories Inc. Enter Into ....

XTEN vs. Other Half-Life Extension Technologies

While PEGylation remains a common strategy, the advantages of XTEN are becoming increasingly apparent.Peptide Therapy: Unlocking the Body's Potential for Healing and ... XTEN offers a biological alternative that is fully recombinant, allowing for precise control over its structure and properties. This contrasts with chemical PEGylation, which can be less predictable.Multivalent Antiviral XTEN–Peptide Conjugates with Long in ... Other strategies for peptide half-life extension, such as albumin-binding domains (ABD), also exist, but XTEN polypeptide provides a distinct mechanism of action.

The development of extended recombinant polypeptide (XTEN) compositions and conjugates highlights the company's commitment to advancing this technology.Extension of in Vivo Half-Life of Biologically Active ... For researchers seeking high-purity reagents, companies like X-Tide Peptides offer high-purity peptides and related compounds, which can complement the use of XTEN in various research settings.Multivalent Antiviral XTEN–Peptide Conjugates with Long in ... The XTEN protein itself can be a valuable tool in biopharmaceutical research and development, enabling the creation of novel therapeutics with significantly improved pharmacokinetic profiles作者：S Ding·2014·被引用次数：80—XTENs areunstructured, nonrepetitive protein polymersdesigned to prolong the in vivo half-life of pharmaceuticals by introducing a bulking ....

In summary, the XTEN peptide represents a significant leap forward in drug delivery technology. Its ability to act like PEG while offering superior biological integration, precise control, and lower immunogenicity makes it a compelling platform for developing next-generation therapeutics. As research continues to uncover the full potential of this unstructured, hydrophilic and biodegradable protein polymer, we can expect to see its application expand across a wider range of diseases and therapeutic areas, ultimately benefiting patients worldwide.